User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.

Primary tabs

Lucas, Stéphane [FUNDP] Feron, Olivier [UCL] Gallez, Bernard [UCL] Masereel, Bernard [FUNDP] Michiels, Carine [FUNDP] Vander Borght, Thierry [UCL]

Radioimmunotherapy has shown that the use of monoclonal antibodies combined with a radioisotope like (131)I or (90)Y still remains ineffective for solid and radioresistant tumour treatment. Previous simulations have revealed that an increase in the number of (90)Y labelled to each antibody or nanoobject could be a solution to improve treatment output. It now seems important to assess the treatment output and toxicity when radionuclides such as (90)Y, (177)Lu, (131)I, (124)I, and (188)Re are used. Tumour control probability (TCP) and normal tissue complication probability (NTCP) curves versus the number of radionuclides per nanoobject were computed with MCNPX to evaluate treatment efficacy for solid tumours and to predict the incidence of surrounding side effects. Analyses were carried out for two solid tumour sizes of 0.5 and 1.0 cm radius and for nanoobject (i.e., a radiolabelled antibody) distributed uniformly or nonuniformly throughout a solid tumour (e.g., Non-small-cell-lung cancer (NSCLC)). (90)Y and (188)Re are the best candidates for solid tumour treatment when only one radionuclide is coupled to one carrier. Furthermore, regardless of the radionuclide properties, high values of TCP can be reached without toxicity if the number of radionuclides per nanoobject increases.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2015
Language Anglais
Journal information "Computational and Mathematical Methods in Medicine" - Vol. 2015, p. 284360 [1-15] (2015)
Peer reviewed yes
Publisher Hindawi Publishing Corporation ((United States) New York, NY)
issn 1748-670X
e-issn 1748-6718
Publication status Publié
Affiliations UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique
UCL - SSS/IREC/MONT - Pôle Mont Godinne
UCL - SSS/LDRI - Louvain Drug Research Institute
UCL - (SLuc) Service de médecine nucléaire
UCL - (MGD) Service de médecine nucléaire
UCL - SSS/IREC - Institut de recherche expérimentale et clinique
Links
  1. Dearling J.L.J., Pedley R.B., Technological Advances in Radioimmunotherapy, 10.1016/j.clon.2007.03.016
  2. Gruaz-Guyon A., Raguin O., Barbet J., Recent Advances in Pretargeted Radioimmunotherapy, 10.2174/0929867053363225
  3. Bethge Wolfgang A., Sandmaier Brenda M., Targeted Cancer Therapy Using Radiolabeled Monoclonal Antibodies, 10.1177/153303460500400407
  4. Govindan Serengulam V., Griffiths Gary L., Hansen Hans J., Horak Ivan D., Goldenberg David M., Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies, 10.1177/153303460500400406
  5. Brechbiel Martin W., Gansow Otto A., Atcher Robert W., Schlom Jeffrey, Esteban Jose, Simpson Diane, Colcher David, Synthesis of 1-(p-isothiocyanatobenzyl) derivatives of DTPA and EDTA. Antibody labeling and tumor-imaging studies, 10.1021/ic00236a024
  6. Nikula Tuomo K., Bocchia Monica, Curcio Michael J., Sgouros George, Ma Yan, Finn Ronald D., Scheinberg David A., Impact of the high tyrosine fraction in complementarity determining regions: measured and predicted effects of radioiodination on IgG immunoreactivity, 10.1016/0161-5890(95)00052-g
  7. Bouchat V., Moreau N., Valembois V., Abbas K., Feron O., Gallez B., Holzwarth U., Masereel B., Michiels C., Simonelli F., Vander Borght T., Lucas S., On the use of radioisotopes to study the possible synthesis by magnetron sputtering of bimetallic nanoparticles, 10.1016/j.surfcoat.2011.04.077
  8. Katti K. V., Kannan R., Katti K., Kattumori V., Pandrapraganda R., Rahing V., Cutler C., Boote E. J., Casteel S. W., Smith C. J., Robertson J. D., Jurrison S. S., Hybrid gold nanoparticles in molecular imaging and radiotherapy, 10.1007/s10582-006-0484-9
  9. Wu Hong, Wang Jun, Wang Zhemin, Fisher Darrell R., Lin Yuehe, Apoferritin-Templated Yttrium Phosphate Nanoparticle Conjugates for Radioimmunotherapy of Cancers, 10.1166/jnn.2008.177
  10. Gref R, Lück M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunk T, Müller R.H, ‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption, 10.1016/s0927-7765(99)00156-3
  11. OWENSIII D, PEPPAS N, Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles, 10.1016/j.ijpharm.2005.10.010
  12. Karmani Linda, Labar Daniel, Valembois Vanessa, Bouchat Virginie, Nagaswaran Praveen Ganesh, Bol Anne, Gillart Jacques, Levêque Philippe, Bouzin Caroline, Bonifazi Davide, Michiels Carine, Feron Olivier, Grégoire Vincent, Lucas Stéphane, Borght Thierry Vander, Gallez Bernard, Antibody-functionalized nanoparticles for imaging cancer: influence of conjugation to gold nanoparticles on the biodistribution of89Zr-labeled cetuximab in mice : PET IMAGING WITH IMMUNOTARGETED NANOPARTICLES, 10.1002/cmmi.1539
  13. Marega Riccardo, Karmani Linda, Flamant Lionel, Nageswaran Praveen Ganesh, Valembois Vanessa, Masereel Bernard, Feron Olivier, Borght Thierry Vander, Lucas Stephane, Michiels Carine, Gallez Bernard, Bonifazi Davide, Antibody-functionalized polymer-coated gold nanoparticles targeting cancer cells: an in vitro and in vivo study, 10.1039/c2jm33482h
  14. Bouchat V., Nuttens V. E., Lucas S., Michiels C., Masereel B., Féron O., Gallez B., Borght T. Vander, Radioimmunotherapy with radioactive nanoparticles: First results of dosimetry for vascularized and necrosed solid tumors : Monte Carlo dosimetry for radioactive nanoparticles, 10.1118/1.2791038
  15. Bouchat V., Nuttens V. E., Michiels C., Masereel B., Feron O., Gallez B., Vander Borght T., Lucas S., Radioimmunotherapy with radioactive nanoparticles: Biological doses and treatment efficiency for vascularized tumors with or without a central hypoxic area : BED and SCP for radioactive nanoparticles, 10.1118/1.3368599
  16. Nagata Yasushi, Takayama Kenji, Matsuo Yukinori, Norihisa Yoshiki, Mizowaki Takashi, Sakamoto Takashi, Sakamoto Masato, Mitsumori Michihide, Shibuya Keiko, Araki Norio, Yano Shinsuke, Hiraoka Masahiro, Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame, 10.1016/j.ijrobp.2005.05.034
  17. Nyman Jan, Johansson Karl-Axel, Hultén Ulla, Stereotactic hypofractionated radiotherapy for stage I non-small cell lung cancer—Mature results for medically inoperable patients, 10.1016/j.lungcan.2005.08.011
  18. Lagerwaard Frank J., Haasbeek Cornelis J., Slotman Ben J., Senan Suresh, B5-04: Clinical results and toxicity after 4-dimensional stereotactic radiotherapy for early stage non-small cell lung cancer (NSCLC), 10.1097/01.jto.0000283170.96480.69
  19. Timmerman Robert, McGarry Ronald, Yiannoutsos Constantin, Papiez Lech, Tudor Kathy, DeLuca Jill, Ewing Marvene, Abdulrahman Ramzi, DesRosiers Colleen, Williams Mark, Fletcher James, Excessive Toxicity When Treating Central Tumors in a Phase II Study of Stereotactic Body Radiation Therapy for Medically Inoperable Early-Stage Lung Cancer, 10.1200/jco.2006.07.5937
  20. Glatting Gerhard, Bardiès Manuel, Lassmann Michael, Treatment planning in molecular radiotherapy, 10.1016/j.zemedi.2013.03.005
  21. Wiseman Gregory A, White Christine A, Sparks Richard B, Erwin William D, Podoloff Donald A, Lamonica Dominick, Bartlett Nancy L, Anthony Parker J, Dunn William L, Spies Stewart M, Belanger Richard, Witzig Thomas E, Leigh Bryan R, Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, 10.1016/s1040-8428(01)00107-x
  22. Pouget Jean-Pierre, Navarro-Teulon Isabelle, Bardiès Manuel, Chouin Nicolas, Cartron Guillaume, Pèlegrin André, Azria David, Clinical radioimmunotherapy—the role of radiobiology, 10.1038/nrclinonc.2011.160
  23. Lauter Anett, Strumpf Annette, Platzbecker Uwe, Schetelig Johannes, Wermke Martin, Radke Jörgen, Kiani Alexander, Wunderlich Gerd, Thiede Christian, Ehninger Gerhard, Kotzerke Jorg, Bornhäuser Martin, 188Re anti-CD66 radioimmunotherapy combined with reduced-intensity conditioning andin-vivoT cell depletion in elderly patients undergoing allogeneic haematopoietic cell transplantation, 10.1111/j.1365-2141.2009.08025.x
  24. Ringhoffer Mark, Blumstein Norbert, Neumaier Bernd, Glatting Gerhard, Harsdorf Stephanie, Buchmann Inga, Wiesneth Markus, Kotzerke Jorg, Zenz Thorsten, Buck Andreas K., Schauwecker Peter, Stilgenbauer Stephan, Dohner Hartmut, Reske Sven N., Bunjes Donald, 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study, 10.1111/j.1365-2141.2005.05663.x
  25. Alvarez Ronald D., Partridge Edward E., Khazaeli M.B., Plott Gene, Austin Max, Kilgore Larry, Russell Charles D., Liu Tiepu, Grizzle William E., Schlom Jeffrey, LoBuglio Albert F., Meredith Ruby F., Intraperitoneal Radioimmunotherapy of Ovarian Cancer with177Lu-CC49: A Phase I/II Study, 10.1006/gyno.1996.4577
  26. The Journal of Nuclear Medicine, 37, 1491 (1996)
  27. Journal of Nuclear Medicine, 46, 850 (2005)
  28. Chaturvedi Richa, Heimburg Jamie, Yan Jun, Koury Stephen, Sajjad Munawwar, Abdel-Nabi Hani H., Rittenhouse-Olson Kate, Tumor immunolocalization using 124I-iodine-labeled JAA-F11 antibody to Thomsen–Friedenreich alpha-linked antigen, 10.1016/j.apradiso.2007.07.029
  29. Journal of Nuclear Medicine, 46, 164S (2005)
  30. Journal of Nuclear Medicine, 37, 1557 (1996)
  31. Nuttens V.E., Wéra A.-C., Bouchat V., Lucas S., Determination of biological vector characteristics and nanoparticle dimensions for radioimmunotherapy with radioactive nanoparticles, 10.1016/j.apradiso.2007.08.017
  32. Howell Roger W., Rao Dandamudi V., Sastry Kandula S. R., Macroscopic dosimetry for radioimmunotherapy: Nonuniform activity distributions in solid tumors : Macroscopic dosimetry for radioimmunotherapy, 10.1118/1.596404
  33. Clinical Cancer Research, 5, 3044s (1999)
  34. Bodey Rachel K., Evans Phil M., Flux Glenn D., Application of the linear-quadratic model to combined modality radiotherapy, 10.1016/j.ijrobp.2003.12.031
  35. Journal of Nuclear Medicine, 35, 1861 (1994)
  36. Mehta Minesh, Scrimger Rufus, Mackie Rock, Paliwal Bhudatt, Chappell Rick, Fowler Jack, A new approach to dose escalation in non–small-cell lung cancer, 10.1016/s0360-3016(00)01374-2
  37. Ruggieri Ruggero, Hypofractionation in non-small cell lung cancer (NSCLC): suggestions from modelling both acute and chronic hypoxia, 10.1088/0031-9155/49/20/011
  38. Baechler Sébastien, Hobbs Robert F., Prideaux Andrew R., Wahl Richard L., Sgouros George, Extension of the biological effective dose to the MIRD schema and possible implications in radionuclide therapy dosimetry : Extension of BED to the MIRD schema, 10.1118/1.2836421
  39. Guerrero Mariana, Li X Allen, Halftime for repair of sublethal damage in normal bladder and rectum: an analysis of clinical data from cervix brachytherapy, 10.1088/0031-9155/51/16/012
  40. Dubray Bernard, Henry-Amar Michel, Meerwaldt Jacobus H., Noordijk Evert M., Dixon Dennis O., Cosset Jean-Marc, Thames Howard D., Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation, 10.1016/0167-8140(95)01606-h
  41. Webb S, Nahum A E, A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density, 10.1088/0031-9155/38/6/001
  42. Seppenwoolde Yvette, Lebesque Joos V., de Jaeger Katrien, Belderbos José S.A., Boersma Liesbeth J., Schilstra Cees, Henning George T., Hayman James A., Martel Mary K., Ten Haken Randall K., Comparing different NTCP models that predict the incidence of radiation pneumonitis, 10.1016/s0360-3016(02)03986-x
  43. Källman P., Ågren A., Brahme A., Tumour and Normal Tissue Responses to Fractionated Non-uniform Dose Delivery, 10.1080/09553009214552071
  44. Burman C., Kutcher G.J., Emami B., Goitein M., Fitting of normal tissue tolerance data to an analytic function, 10.1016/0360-3016(91)90172-z
  45. Annals of Oncology, 10, S77 (1999)
Bibliographic reference Lucas, Stéphane ; Feron, Olivier ; Gallez, Bernard ; Masereel, Bernard ; Michiels, Carine ; et. al. Monte Carlo Calculation of Radioimmunotherapy with (90)Y-, (177)Lu-, (131)I-, (124)I-, and (188)Re-Nanoobjects: Choice of the Best Radionuclide for Solid Tumour Treatment by Using TCP and NTCP Concepts.. In: Computational and Mathematical Methods in Medicine, Vol. 2015, p. 284360 [1-15] (2015)
Permanent URL http://hdl.handle.net/2078.1/164938